Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial

Science Translational Medicine(2023)10.1126/scitranslmed.ade9078Source: DataRank Database

Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial is a research paper published in Science Translational Medicine (2023). On theSindex it has a DataRank of 1.3. It has been cited 48 times, with 25 citing works in its 1-hop citation network.

N/A

1.3DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access48 citations · 25 citing works in its network

Download PDF

Cite:

Linked data & code

gen nct

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT04470427

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (11 grants)Impact (FWCI 8.24)OA: hybridTopics (39)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 45%Citation Network 55%

Base Score Contribution

0.584

From this paper's citation signal

Citation Network Contribution

0.726

From 17 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 25 citers.

Risk factors and correlates of protection against XBB SARS-CoV-2 infection among health care workers
Vaccine20246 citations10 referencesContributes 0.195
Immune correlates analysis of mRNA-1345 RSV vaccine efficacy clinical trial
Nature Communications202522 citations32 referencesContributes 0.098
Comparative antibody and cell-mediated immune responses, reactogenicity, and efficacy of homologous and heterologous boosting with CoronaVac and BNT162b2 (Cobovax): an open-label, randomised trial
The Lancet Microbe202325 citations38 referencesContributes 0.086
Effect of timing of casirivimab and imdevimab administration relative to mRNA-1273 COVID-19 vaccination on vaccine-induced SARS-CoV-2 neutralising antibody responses: a prospective, open-label, phase 2, randomised controlled trial
The Lancet Infectious Diseases20247 citations30 referencesContributes 0.069
Anti–SARS-CoV-2 Antibody Levels Associated With COVID-19 Protection in Outpatients Tested for SARS-CoV-2, US Flu Vaccine Effectiveness Network, October 2021–June 2022
The Journal of Infectious Diseases20249 citations34 referencesContributes 0.068

Authors (48)

David C. Montefiori ORCID,Adrian B. McDermott ORCID,Youyi Fong ORCID,Holly Janes ORCID,Weiping Deng ORCID

Live enrichment

PubMed:37075127 PMC:PMC10243212 OpenAlex:https://openalex.org/W4366371403

NIAID NIH HHS

Grant: UM1 AI148684

NIAID NIH HHS

Grant: UM1 AI068614

NIAID NIH HHS

Grant: R37 AI054165

NIAID NIH HHS

Grant: UM1 AI068635

NIAID NIH HHS

Grant: S10 AI174104

NIAID NIH HHS

Grant: UM1 AI148685

NIH HHS

Grant: S10 OD028685

National Institutes of Health

Grant: 3UM1AI148684-03S1

Leadership Group for the Infectious Diseases Clinical Research Consortium (IDCRCLG)

National Institutes of Health

Grant: 1S10OD028685-01

High-Performance Compute Cluster for Comprehensive Cancer and Infectious Diseases Research

National Institutes of Health

Grant: 3UM1AI068635-17S4

CoVPN 3001 - A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults.

National Institutes of Health

Grant: 5R37AI054165-12

Statistical Methods in HIV Vaccine Efficacy Trials

FWCI

8.24

Citation Percentile

1.0%

Citation Trend

2023

2024

2025

2026

hybridLicense: cc-by

journalhttps://www.science.org/doi/pdf/10.1126/scitranslmed.ade9078?download=true

publisherhttps://www.science.org/doi/pdf/10.1126/scitranslmed.ade9078?download=true

publisherhttps://www.science.org/doi/pdf/10.1126/scitranslmed.ade9078

journalhttps://doi.org/10.1126/scitranslmed.ade9078

repositoryhttps://pubmed.ncbi.nlm.nih.gov/37075127

Fields of Study

SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections StudiesSARS-CoV-2 detection and testing0303 health sciences03 medical and health sciences

MeSH Terms

COVID-19Vaccine Efficacy2019-nCoV Vaccine mRNA-1273Antibodies, ViralHumansImmunoglobulin GAntibodies, Neutralizing

Keywords

Coronavirus disease 2019 (COVID-19)VirologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakVaccine trialMedicineVaccine efficacyAntibodyClinical trialMessenger RNABiologyImmunologyPharmacologyVaccinationInternal medicineOutbreakGeneInfectious disease (medical specialty)GeneticsDiseaseImmunoglobulin GHumansCOVID-19Antibodies, ViralAntibodies, NeutralizingArticle2019-nCoV Vaccine mRNA-1273

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being